Hypoglycemic Agent YM440 Ameliorates the Impaired Hepatic Glycogenesis After Glucose Loading by Increasing Glycogen Synthase Activity in Obese Zucker Rats
スポンサーリンク
概要
- 論文の詳細を見る
We studied the role of hepatic glycogenesis in glucose intolerance after glucose loading in obese Zucker rats and the effects of YM440 ((Z)-1,4-bis{4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy}but-2-ene) on it. Lean and obese Zucker rats were treated with YM440 (300 mg/kg) for 14 days and then fasted for 20 h. Thirty percent glucose (0.6 g/kg) or saline was administered intravenously followed by NaH14CO3. Gluconeogenesis was evaluated based on the incorporation of 14C-bicarbonate into blood glucose and hepatic glycogen. Obese rats showed an increase in the incorporation of 14C into blood glucose of 2.5-fold compared to lean rats. The glucose loading decreased the 14C-blood glucose release by 18% in obese rats and 43% in lean rats at 45 min. Glucose loading increased the hepatic glycogen content and 14C incorporation into glycogen in lean but not obese rats. YM440 decreased levels of fasting plasma insulin and blood glucose and the hepatic glycogen content by 50% compared with values for untreated obese rats. After glucose loading, YM440 promoted the incorporation of 14C into glycogen and glycogen synthase activity, leading to an improvement in glucose tolerance. These results indicate that glucose intolerance in obese rats was associated with decreased hepatic glycogenesis and YM440 improved the intolerance by normalizing glycogen metabolism.
- 社団法人 日本薬理学会の論文
- 2002-07-01
著者
-
Shibasaki Masayuki
Pharmacology Research Laboratories Drug Discovery Research Astellas Pharma Inc.
-
Shibasaki Masayuki
Pharmacology Laboratories Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.
-
Shikama Hisataka
Pharmacology Laboratories Institute For Drug Discovery Research Yamaguchi Pharmaceutical Co Ltd.
-
Nakano Ryosuke
Pharmacology Research Laboratories Drug Discovery Research Astellas Pharma Inc.
-
KUROSAKI Eiji
Pharmacology Laboratories Institute for Drug Discovery Research, Yamaguchi Pharmaceutical Co Ltd.
-
MOMOSE Kazuhiro
Pharmacology Laboratories Institute for Drug Discovery Research, Yamaguchi Pharmaceutical Co Ltd.
-
SHIMAYA Akiyoshi
Pharmacology Laboratories Institute for Drug Discovery Research, Yamaguchi Pharmaceutical Co Ltd.
-
SUZUKI Takayuki
Chemistry Laboratories Institute for Drug Discovery Research, Yamaguchi Pharmaceutical Co Ltd.
-
Kurosaki Eiji
Pharmacology Research Laboratories Drug Discovery Research Astellas Pharma Inc.
-
Momose Kazuhiro
Pharmacology Laboratories Institute For Drug Discovery Research Yamaguchi Pharmaceutical Co Ltd.
-
Suzuki Takayuki
Chemistry Laboratories Institute For Drug Discovery Research Yamaguchi Pharmaceutical Co Ltd.
-
Nakano Ryosuke
Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd.
関連論文
- YM-231146, a Novel Orally Bioavailable Inhibitor of Vascular Endothelial Growth Factor Receptor-2, Is Effective against Paclitaxel Resistant Tumors(Pharmacology)
- The Novel Hypoglycemic Agent YM440 Improves Hepatic Insulin Resistance in Obese Zucker Fatty Rats
- The Novel Hypoglycemic Agent YM440 Improves Hepatic Insulin Resistance in Obese Zucker Fatty Rats
- Hypoglycemic Agent YM440 Ameliorates the Impaired Hepatic Glycogenesis After Glucose Loading by Increasing Glycogen Synthase Activity in Obese Zucker Rats